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Abstract 
 The genetic alterations in pediatric gliomas can be used as diagnostic and prognostic 
markers and are the basis for the development of new target therapies that, ideally, would be 
associated with less mortality and morbidity.  
 The aim of this study was to determine the genetic profile of pediatric gliomas and to do 
the translation of the genetic data for the clinical and laboratorial practice. Thus, the frequency 
of alterations in BRAF, CDKN2A, MYB, MYBL1, FGFR1, H3F3A, H3F3B and HIST1H3I genes were 
analyzed in 109 pediatric gliomas using Fluorescent In Situ Hybridization (FISH) and Sequencing 
using Sanger methodology. 
 In the present project we found that the BRAF/KIAA1549 rearrangement was associated 
with cerebelar pilocytic astrocytomas and was exclusive of low-grade gliomas, being useful as a 
diagnostic marker. The BRAFV600E mutation was associated with a better patients’ overall 
survival and the deletion of the CDKN2A gene was associated with tumor recurrences. So, these 
two genetic alterations may be used as prognostic markers in pediatric gliomas. A cell line was 
established from a high-grade glioma that harbor the BRAFV600E mutation. The identification 
of MYB, MYBL1 and FGFR1 rearrangements by FISH did not seem to be useful as diagnostic or 
prognostic markers. K27M and G34R/V mutations were identified in the H3F3A gene and were 
shown to be exclusive of high-grade gliomas and to vary with the tumor location and patients´ 
age. 
 In sum, it was determined, for the first time, the genetic profile of pediatric gliomas in 
the Portuguese population and it was demonstrated that it is useful to the tumor 
characterization, with prognostic and diagnostic information. In this context, the establishment 
of cell lines from tumors with specific genetic alterations, such as the BRAFV600E mutation, may 
be the basis for susceptibility trials to new drugs and for a better understanding of the disease.  
 
Key-words: pediatric gliomas; BRAF gene; MYB, MYBL1 and FGFR1 genes; CDKN2A gene; histone 
genes  
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Resumo 
As alterações genéticas presentes em gliomas pediátricos constituem importantes 
marcadores de diagnóstico e prognóstico e são base para o desenvolvimento de novas formas 
terapêuticas, que se espera, impliquem menor mortalidade e morbilidade.  
Neste trabalho avaliámos a frequência de alterações nos genes BRAF, CDKN2A, MYB, 
MYBL1, FGFR1, H3F3A, H3F3B e HIST1H3I com o objetivo de determinar o perfil genético dos 
gliomas pediátricos que foram referidos ao IPOLFG, e fazer a translação dos dados genéticos 
para a prática clínica e laboratorial. Assim, 109 tumores foram analisados por “Fluorescent In 
Situ Hybridization (FISH)” e por sequenciação pelo método de Sanger.  
Foi observado que o rearranjo BRAF/KIAA1549 estava associado a astrocitomas 
pilocíticos com localização cerebelar e era exclusivo dos gliomas de baixo grau, sendo útil como 
marcador de diagnóstico nestes tumores. A mutação BRAFV600E estava associada a uma maior 
sobrevivência dos pacientes e a deleção do gene CDKN2A com a ocorrência de recidivas. Assim, 
parece que estas duas alterações genéticas podem ser usadas como marcadores de prognóstico 
em gliomas pediátricos. Foi estabelecida uma linha de cultura a partir de um glioma de alto grau 
com a mutação BRAFV600E. A identificação, por FISH, de rearranjos nos genes MYB, MYBL1 e 
FGFR1, não pareceu ser útil a nível de diagnóstico ou prognóstico. Nos genes das histonas, as 
mutações K27M e G34R/V eram exclusivas dos gliomas de alto grau e só foram observadas no 
gene H3F3A. Estas mutações estavam associadas à localização do tumor e idade do paciente. 
Em suma, foi caracterizado, pela primeira vez, o perfil genético de gliomas pediátricos 
na população portuguesa e foi demonstrada a sua utilidade para a caracterização tumoral, com 
informação diagnóstica e prognóstica. Neste contexto, o estabelecimento de linhas tumorais 
com alterações genéticas, como a mutação BRAFV600E, pode servir de base para ensaios de 
susceptibilidade a novos fármacos e para um melhor conhecimento da doença. 
 
 
Palavras-chave: gliomas pediátricos; BRAF; MYB, MYBL1 e FGFR1; CDKN2A; genes das histonas 
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Resumo Alargado 
Os tumores primários do Sistema Nervoso Central (SNC) são a seguir às leucemias, os 
tumores pediátricos mais frequentes e constituem a principal causa de morte, por cancro, em 
crianças e adolescentes com menos de 20 anos de idade. Estes tumores estão também 
associados a uma elevada taxa de morbilidade provocada pelos tratamentos (cirurgia, 
radioterapia e quimioterapia) a que estas crianças são habitualmente sujeitas 1. 
Os gliomas são o tipo histológico mais comum dos tumores pediátricos do SNC e têm a 
sua origem no tecido neuroepitelial e nas células da glia. De acordo com a última classificação 
da Organização Mundial de Saúde, de 2007, estes tumores são subdivididos em quatro 
subgrupos histológicos principais: (I) Tumores astrocíticos; (II) Tumores oligodendrogliais; (III) 
Tumores neuronais e neurogliais; (IV) Ependimomas. Este último subgrupo é geralmente 
excluído desta classificação, sendo considerado uma doença distinta. Posteriormente, os 
gliomas são classificados de acordo com a sua malignidade em 4 graus (I-IV), sendo o grau I o 
menos e o grau IV o mais agressivo 2. No entanto, devido à sua grande heterogeneidade, a 
classificação histológica e biológica dos gliomas pediátricos, não é na maior parte das vezes fácil, 
pelo que o risco de sobre-tratamento, com todos os efeitos secundários daí decorrentes, é 
grande. Esta situação começou a alterar-se em 2012 com o surgimento de trabalhos de 
sequenciação massiva dos vários tipos de gliomas, que permitiram classificar tumores 
histologicamente idênticos em sub-grupos genéticos e epigenéticos distintos 1.  
Assim, um conjunto de alterações genéticas começou a ser identificado como 
característico dos gliomas pediátricos. Por exemplo, no contexto dos gliomas de baixo grau, foi 
verificado que o rearranjo do gene BRAF, que resulta na formação do gene de fusão 
BRAF/KIAA1549 era exclusivo deste tipo de gliomas e característico de astrocitomas pilociticos; 
que a mutação BRAFV600E embora comum, não era exclusiva destes gliomas; e que a existência 
de rearranjos nos genes MYB, MYBL1 e FGFR1 poderia estar relacionada com os gliomas 
pediátricos difusos (gliomas de baixo grau com comportamento infiltrativo) 3–6.  
Todas estas alterações genéticas identificadas em gliomas de baixo grau levam a uma 
activação da via de sinalização MAPK/ERK. Assim, levantou-se a hipótese de os gliomas 
pediátricos de baixo grau serem uma “doença de uma única via de sinalização” 7. Visto que a 
activação da via MAPK/ERK pode resultar tanto em proliferação, sobrevivência e tumorigénese, 
como em diferenciação e senescência celular, foi possível perceber o porquê dos gliomas de 
baixo grau raramente se tornarem tumores de alto grau. Neste contexto, foi demonstrado que 
a deleção do gene CDKN2A em gliomas pediátricos com alterações no gene BRAF estava 
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associada a tumores mais agressivos, provavelmente por refletir uma falha ou em escape da 
senescência celular induzida 5,8,9.  
Por outro lado, as mutações K27M e G34R/V nas histonas H3.3 e H3.1 são exclusivas dos 
gliomas pediátricos de alto grau. Enquanto a mutação K27M na histona H3.1 parece ser exclusiva 
de “diffuse intrinsic pontine gliomas” (tumor agressivo com localização no tronco cerebral) e 
glioblastomas não localizados no tronco cerebral; a mutação K27M na histona H3.3 é específica 
de tumores com localização na linha média e de pacientes mais jovens, e as mutações G34R/V 
da mesma histona só foram observadas em tumores de pacientes mais velhos e localizados no 
córtex cerebral. A mutação K27M na histona H3.3 está também associada a um pior prognóstico, 
relativamente à mutação G34R/V 10–13. 
O objectivo deste trabalho é determinar, retrospectivamente, o perfil genético dos 
gliomas pediátricos referidos ao IPOLFG e fazer a translação dos dados genéticos para a prática 
laboratorial. Para isso, foi investigada, numa série de 109 gliomas pediátricos, a frequência de 
alterações nos genes BRAF, MYB, MYBL1, FGFR1, CDKN2A, H3F3A, H3F3B e HIST1H3I. Para além 
de terem sido relacionadas com a classificação histológica e a localização do tumor, a idade e 
género do paciente, estas alterações genéticas foram, também, identificadas em linhas celulares 
estabelecidas a partir de tumores. Assim, a parte experimental deste trabalho foi dividida em 
três fases principais: a primeira consistiu numa análise por “Fluorescent In Situ Hybridization 
(FISH)”, a segunda na sequenciação pelo método de Sanger, e a terceira em cultura celular. 
Enquanto a técnica FISH foi utilizada para identificar o rearranjo BRAF/KIAA1549, os rearranjos 
dos genes MYB, MYBL1 e FGFR1, e a deleção do gene CDKN2A; a sequenciação pelo método de 
Sanger foi utilizada para identificar mutações nos genes BRAF, H3F3A, H3F3B e HIST1H3I. As 
amostras dos gliomas foram recebidas em material fresco ou embebidas em parafina. 
  Dos 109 gliomas estudados, 67 eram de grau I, 13 de grau II, 14 de grau III, 8 de grau IV 
e 7 com classificação histológica não especificada. Na série de gliomas pediátricos analisados, 
como descrito na literatura, a presença do rearranjo BRAF/KIAA1549 era exclusiva dos gliomas 
baixo grau e estava relacionada com a histologia de astrocitoma pilocítco (p-value <0.0001) e 
com tumores localizados no cerebelo (p-value <0.0001). Estes resultados sugerem que a 
identificação deste rearranjo genético na prática laboratorial tem utilidade como marcador de 
diagnóstico em gliomas pediátricos de baixo grau. A ocorrência da mutação BRAFV600E era 
independente do tipo histológico e localização do tumor bem como da idade ou género do 
paciente. No entanto, estava associada a uma maior sobrevivência dos pacientes (p-
value=0.0443). Apesar de serem necessários mais estudos em séries maiores de gliomas 
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pediátricos, os nossos resultados sugerem que utilização desta mutação como marcador de 
prognóstico pode ser útil. Além disto, durante este trabalho foi estabelecida uma linha de 
cultura a partir de um glioma de alto grau com a mutação BRAFV600E que poderá servir de base 
para ensaios de susceptibilidade a novos fármacos e para um melhor entendimento da doença 
a nível molecular. 
Quanto à deleção do gene CDKN2A foi verificado que a sua incidência aumentava com 
o grau dos tumores: 10% nos gliomas de grau I, 30% nos de grau II e III, e 42.9% nos de grau IV. 
Além disso, todos os gliomas de baixo grau apresentavam uma deleção heterozigótica deste 
gene e só em três gliomas de alto grau foram identificadas deleções homozigóticas do gene 
CDKN2A. Esta alteração genética mostrou estar relacionada com a ocorrência de recidivas (p-
value=0.0149), sugerindo a sua utilização como marcador de prognóstico em gliomas 
pediátricos.  
A identificação, por FISH, de rearranjos nos genes MYB, MYBL1 e FGFR1, não pareceu 
ser útil a nível de diagnóstico ou prognóstico visto que na série de gliomas estudados só foi 
identificado um rearranjo do gene MYB num glioma com classificação histológica não 
especificada, um rearranjo do gene MYBL1, não descrito anteriormente, num astrocitoma 
pilocítico e nenhum rearranjo do gene FGFR1. 
As mutações K27M e G34R/V só foram identificadas no gene H3F3A e, como descrito na 
literatura, estavam relacionadas com a localização do tumor e idade dos pacientes. Foi também 
possível verificar que estas mutações não são exclusivas dos astrocitomas pediátricos de alto 
grau, estando presentes noutros gliomas de alto grau como tumores oligoastrocíticos e 
oligodendrogliais. Isto levanta a hipótese de a classificação usada hoje em dia para a 
estratificação dos glioblastomas poder ser estendida para outros subtipos histológicos de 
gliomas de alto grau. 
Assim, com este trabalho, foi possível verificar que o perfil genético de gliomas 
pediátricos pode ser útil para melhorar a classificação tumoral, tanto com informação 
diagnóstica como prognóstica, e para melhorar o conhecimento da doença, o que idealmente, 
contribuirá para o desenvolvimento de terapias mais eficazes. 
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I - Introduction: 
 
1 - Pediatric Tumors of the Central Nervous System (CNS): 
Tumors of the CNS account for 20-25% of all pediatric cancer diagnoses in the developed 
world 14,15, being the most prevalent group of cancers in children, after leukemia 15. Although 
uncommon, pediatric brain tumors represent the leading cause of cancer-related mortality in 
children and adolescents aged 20 years and under 1,15–17; and the third leading cause of cancer-
related death in young adults aged 20 to 39 years 1. In addition to their relatively high mortality, 
CNS tumors are associated with extensive morbidities such as pituitary dysfunction, growth 
hormone deficiency, epilepsy, vision loss, impaired motor skills, memory dysfunction, attention 
and behavioral disorders and reduced IQ. So, about 90% of survivors are left with long term 
cognitive and psycho-social deficits 15. 
Diagnosis of pediatric CNS tumors is traditionally based on histological grading. CNS 
tumors are classified according to World Health Organization (WHO) criteria based on cell 
morphology and location of the tumor. According to the last classification, from 2007, the main 
tumor classes are the following: neuroepithelial, cranial and paraspinal nerve, meningeal, 
lymphoma and hematopoietic, germ cell, sellar region and metastatic. Tumors are further 
segregated into distinct histological grades, from WHO grade I to WHO grade IV, on the basis of 
defined cytological and histological features, including cellularity, mitotic activity, nuclear atypia, 
microvascular proliferation and necrosis. The WHO grading scheme functions as a malignancy 
scale (grade I being the least and grade IV the most aggressive), as represented in Figure I.1 2. 
Gliomas are the most common histological type of primary CNS tumors in children 1; 
they are a heterogeneous group of tumors that have neuroepithelial tissue origin and originate 
from glial cells (astrocytes, oligodendrocytes and ependymal cells) 18. So, there are four major 
histologic classes of gliomas: (I) Astrocytic tumors; (II) Oligodendroglial tumors; (III) Neuronal 
and Mixed Neuroglial tumors, (IV) Ependymomas 1,19,20, often excluded from the glioma 
classification and regarded as a distinct disease 14 (see Figure I.1). 
Pediatric Low-grade Gliomas (PLGGs) account for nearly half  of all pediatric CNS tumors 
7,21, comprising a diverse group of WHO Grade I and II tumors 7 that are generally categorized as 
nondiffuse or diffuse based on their extent of brain inﬁltration. Nondiffuse tumors, such as 
pilocytic astrocytomas, exhibit minimal inﬁltration, are predominantly benign and are often 
cured by surgery alone. In contrast, diffuse tumors such as diffuse astrocytomas, 
oligoastrocytomas and oligodendrogliomas, are associated with less favorable clinical outcomes, 
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including recurrence after initial resection, by virtue of their extensive inﬁltration and invasion 
into the brain 16 (Figure I.1).  
Pediatric High-grade Gliomas (PHGG) comprise WHO Grade III and WHO Grade IV 
gliomas and remain one of very few incurable pediatric cancers, with a long-term survival rate 
of less than 10% 19. The most common histological subtypes are glioblastoma  anaplastic 
astrocytoma and anaplastic oligodendroglioma 19 and they account for 15-20% of pediatric brain 
tumors 7. 
Due to the great heterogeneity and histologic overlap, some tumors cannot be 
categorized and are often referred to as Not Otherwise Specified gliomas (NOS). In low-grade 
gliomas, this entity represents nearly one-third of all PLGGs 16. 
 
2 - Tumorigenesis 
Cancer is a genetic disease that involves dynamic changes in the genome. So, despite 
the existence of distinct types of human cancer, the development of genomic instability and 
epigenetic modifications are essential for normal cells to acquire a variety of characteristics 
(such as self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programed cell death and immune destruction, limitless replicative potential, sustained 
Figure I.1 – Classification of gliomas. (A) WHO Grading of Gliomas, adapted from Louis, et al (2007)2. (B) 
Schematic representation of pediatric low-grade gliomas in diffuse and nondiffuse gliomas 16 
 
 
3 
 
angiogenesis, tissue invasion and metastasis, and changes in cellular metabolism) that will rule 
their transformation into malignant cells 22,23. 
For example, in the context of the development of genomic instability, the activating 
mutations or genetic rearrangements, affecting the structure of the B-Raf protein and resulting 
in a constitutive activation of mitogen-activated protein kinase (MAPK) pathway, are tightly 
related with the growth factor independence in tumor cells, contributing to uncontrolled cell 
proliferation. Another example is related with the insensitivity to growth-inhibitory signals in 
cancer cells that are tightly related with somatic, loss of function mutations or genetic 
rearrangements involving tumor suppressor genes (such as RB1 and TP53 genes). The loss of 
function of TP53 gene is also associated with evasion to apoptosis 23. 
In the context of epigenetic modifications, the repression of some genes through 
promoter methylation and the de-repression of others through demethylation, may also 
contribute importantly to tumor progression, not only in the cancer cells but also in the altered 
cells of the tumor-associated stroma 22,23. Moreover, hypomethylation (demethylation of 
normally methylated sequences) has been associated with an extensive chromosomal instability 
which may favors tumor progression 22. 
Like cancer, in general, gliomas develop as a result of genetic alterations that 
accumulate with tumor progression. Given the existent data that show that genetic alterations 
in gliomas vary according to the age of the patient, location, histology and tumor grade 1, it is 
becoming clear that information derived from cytogenetics and molecular genetics will play an 
increasingly more important role in tumor classification, particularly with respect to providing 
more precise diagnostic and prognostic information about particular tumors. So, incorporating 
these findings as companion diagnostics to routine pathology seems to be essential for better 
stratifying tumors and for the development of targeted treatments 3. However, molecular 
diagnostics have only recently begun to be incorporated into the initial evaluation of CNS tumors 
20. 
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3 - Pediatric Low-grade Gliomas (PLGGs)  
PLGGs have been defined by MAPK/ERK pathway activation through a number of well-
defined genetic aberrations 3,7, supporting the concept that PLGG is a “single pathway disease” 
(see Figure I.2) 1,5.  
 
 
3.1 – BRAF-driven gliomas 
About 95% of Grade I gliomas are characterized by defects in BRAF proto-oncogene, in 
the 7q34 region 3, that encodes the B-Raf protein, an intracellular serine-threonine kinase 
member of the Raf kinase family that regulates the MAPK pathway signaling 1,5. This pathway 
normally begins with the activation of a transmembrane receptor tyrosine kinase, which binds, 
phosphorylates and activates Ras, which in turn activates a Raf kinase, in turn activating 
MEK1/2, leading to activation of the ERK1/2 transcription complex (see Figure I.2) 5.  
Under normal circumstances, B-Raf N-terminal regulatory domain inhibits its C-terminal 
kinase domain. When Ras activates B-Raf, it binds to the N-terminal domain of B-Raf, the 
inhibition is released, and MEK is phosphorylated by the Raf kinases 5. Thus, activating mutations 
or genetic rearrangements, affecting the N-terminal regulatory domain of B-Raf may result in a 
constitutive activation of MAPK pathway, involved in tumorigenesis 5. 
Figure I.2 – Overview of the major known 
mutations in PLGG. In this figure the strikes 
indicate the genes known to be altered in PLGGs: 
BRAF, MYB (c-MYB), MYBL1, FGFR1 and NF1. The 
majority of the known genetic alterations in 
PLGGs lead to MAPK/ERK pathway activation. In 
some cases, the PI3K pathway is also activated. 
Adapted from Raabe, et al (2013). © 2013 
American Association for Cancer 
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In PLGGs, the most common genetic alteration involving the BRAF gene is a tandem 
duplication and rearrangement between BRAF and a gene centromeric to BRAF, KIAA1549 5,19, 
as demonstrated in Figure I.3. There are five known variants of this genetic rearrangement. The 
most frequent is the one that occurs between exon 16 of KIAA1549 and exon 9 of BRAF 24. The 
mechanism leading to BRAF/KIAA1549 rearrangement is unclear. However, recent studies 
suggest that the process of microhomology-mediated break-induced replication may be 
involved in the generation of these structural rearrangements 1. The end result of this genetic 
rearrangement is a fusion protein in which the N-terminus of the protein encoded by KIAA1549 
gene is fused with the C-terminus of the protein encoded by BRAF gene, preserving the BRAF 
kinase domain 25. Consequently, it leads to the expression of the B-Raf protein that lacks its N-
terminal auto-inhibitory domain and is constitutively active, resulting in the activation of the 
MAPK/ERK pathway 1,3,21.  
The normal function of the KIAA1549 gene is not known. However its participation in 
the fusion is apparently not critical because there are other alternative BRAF fusion partners 
such as FAM131B, SRGAP3, MACF1, RNF130, CLCN6, MRKN1 and GNAI1 genes that also result 
in an equally potent BRAF activation through loss of the N-terminal auto-regulatory domain 5,7,26. 
 
 
The BRAF/KIAA1549 rearrangement has been tightly correlated with pilocytic 
astrocytoma morphology 5,6. However, Horbinski et al (2013)5 and Gierke, et al (2015)21 have 
observed that the frequency of this genetic rearrangement lessens with age, from approximately 
80% in the first decade of life to 50% in the second decade, and less than 10% of pilocytic 
astrocytomas in patients over 40 years. In children (first two decades of life), the BRAF/KIAA1549 
rearrangement is nearly ubiquitous in posterior fossa pilocytic astrocytomas7. 
Cerebellar  astrocytomas  are  the  most  frequent posterior fossa tumors in children and nearly 
Figure I.3 – Schematic representation of BRAF/KIAA1549 rearrangement. The 
BRAF/KIAA1549 rearrangement is a result of a tandem duplication and fusion between BRAF and 
KIAA1549 genes. Adapted from Forshew, et al (2009)24. 
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80% of cerebellar pilocytic astrocytomas have this BRAF/KIAA1549 rearrangement, compared 
to 50%–55% of non-cerebellar pilocytic astrocytomas 5. However, the BRAF/KIAA1549 fusion is 
also described in diffuse low-grade gliomas 7, though with lower incidences (15%). In PHGG the 
rearrangement is rarely seen 5, suggesting that this genetic alteration is exclusive of PLGG. The 
BRAF/KIAA1549 rearrangement also appears to be a relatively favorable prognostic marker 9. 
Besides the BRAF/KIAA1549 rearrangement, several other different genetic alterations 
that transform the B-Raf kinase into a constitutively activated form have been reported to occur 
in PLGGs 19,21. One of these alterations is the BRAFV600E mutation, a somatic mutation causing 
substitution of the amino acid valine by glutamic acid, at codon 600 5,7. Such somatic activating 
BRAF mutations are observed in up to 7% of human cancers and occur most frequently in 
malignant melanomas (60%) and papillary thyroid carcinomas (40-50%) 4,5,21.  
Under normal circumstances, when B-Raf is activated by Ras (see Figure I.2), T599 and 
S602 amino acids, within the B-Raf activation segment, require phosphorylation to achieve 
maximal kinase activity. It was shown that, in human diseases, amino acids can be mutated to 
acidic residues to mimic phosphorylation and consequently activate kinases. Thus, it is thought 
that BRAFV600E mutation mimics the phosphorylation of the activating amino acids T599 and 
S602, thereby leading to constitutive activation of the protein B-Raf which activates the MAPK 
pathway in a Ras-independent manner 4,27. 
This activating point mutation is highly prevalent in WHO Grade II pleomorphic 
xanthoastrocytomas 3,4 and in anaplastic pleomorphic xanthoastrocytomas 4. The BRAFV600E 
mutation was also described to occur in 33% of the gagliogliomas, in 23% of the diffuse 
astrocytomas 3 and, in 10% of the glioblastomas 28. As BRAF mutation rarely occur in conjunction 
with a BRAF/KIAA1549 rearrangement in the same tumor 5, its incidence in pilocytic 
astrocytomas is low, around 6-9% 3,4. 
The majority of BRAF-driven gliomas are low-grade and tend to stay that way 5. This may 
be explained because the activation of the MAPK/ERK pathway can result in proliferation, 
survival and tumorigenesis but it can also trigger cell differentiation and senescence 5 (see Figure 
I.4). Raabe, et al (2011)8 demonstrated this MAPK/ERK pathway duality in a pilocytic 
astrocytoma model with constitutive BRAF activation: initially the expression of the BRAFV600E 
mutation strongly promoted colony formation, without leading to significantly increased 
proliferation, but subsequently, oncogene-induced senescence limited proliferation. 
Moreover, it was shown by Horbinski, et al (2012)9 that the CDKN2A gene deletion in 
BRAF-driven gliomas had an adverse impact in the tumors’ outcomes. The CDKN2A gene (cyclin-
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dependent kinase inhibitor 2A) located in the 9p21 region, coded a tumor suppressor protein – 
p16. The p16 protein acts as a negative regulator of the proliferation of normal cells, controlling 
the progression through G1 into the S phase of the cell cycle. It interacts with the cyclin-
dependent kinases CDK4 and CDK6, inhibiting theirs ability to interact with cyclins D and, 
consequently, to phosphorylate the retinoblastoma protein (encoded by the RB1 gene). This 
results in the non-release of E2F transcription factor that activates genes involved in the G1-S 
transition 22 (see Figure I.4). Thus, the worst outcomes associated with CDKN2A gene deletion 
can be explained because it was shown that CDKN2A deletion in BRAF-driven tumors could 
reflect a failure to induce senescence or an escape from the induced tumor senescence 8. 
This CDKN2A gene deletion was also reported in several PHGGs with MAPK/ERK pathway 
activation 11,29. However, in PHGGs this pathway activation is usually accompanied by 
impairment of the p53/Rb cell cycle pathway, which could explain why these tumors undergo 
progression rather than senescence 9. 
Mistry, et al (2015)30 demonstrated that BRAFV600E mutations and CDKN2A deletions 
constituted a clinically distinct subtype of pediatric secondary high-grade gliomas that arise from 
a primary PLGG, suggesting that these two genetic alteration may play a role in the malignant 
transformation of PLGGs. 
 
Another mechanism that activates the MAPK/ERK pathway in PLGGs are alterations, 
such as mutations or deletion, of the NF1 gene (at 17q11.2), as represented in Figure I.2. The 
NF1 gene is a tumor suppressor gene that encodes the Neurofibromin 1 protein. In normal 
Figure I.4 – The role of CDKN2A gene in BRAF-driven gliomas: The activation of the MAPK/ERK 
pathway leads to the expression of the tumor suppressor gene CDKN2A. The p16 protein (coded by 
CDKN2A gene) blocks the hyperphosphorylation of Rb (retinoblastoma protein) by inhibitory binding to 
the kinase CDK4/6. This keeps E2F transcription to bind to Rb, resulting in a permanent cell cycle stop in 
G1 phase (senescence). Adapted from Braig, 200748 (available in: http://edoc.hu-
berlin.de/dissertationen/braig-melanie-2007-10-25/HTML/chapter1.html) 
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circumstances, this protein acts as a negative regulator of Ras in the MAPK/ERK pathway, 
preventing cell overgrowth. Alterations in NF1 gene are related with Neurofibromatosis type 1, 
which is a hereditary tumor syndrome associated with the appearance of neurofibromas, 
gliomas and malignant peripheral nerve sheath tumors. In PLGGs, the NF1-related tumors 
account for less than 15% of the cases 3,31.  
3.2 – Grade II Gliomas 
Zhang, et al (2013)3 reported, in their series of pediatric gliomas, that 56% of grade II 
gliomas were characterized by mutually exclusive gene rearrangements inducing gain of 
function of the MYB, MYBL1 and FGFR1 genes. 
3.2.1 – MYB and MYBL1 genes 
The myb gene family consists of three members, named A-myb (8q22), B-myb (20q13) 
and c-myb (6q22), which encode nuclear proteins that function as transcriptional transactivators 
(MYBL1, MYBL2 and MYB, respectively). Although these three genes share an extensive 
homology, their expression and biological functions are different 14,32. While MYB and MYBL1 
genes expression is restricted to specific cell types and stages of development, MYBL2 gene is 
expressed in all proliferating cells 32. So, the MYB gene is highly expressed in proliferation 
epithelial, endothelial and hematopoietic cells and the MYBL1 gene expression is restricted to 
the developing mammary gland, spermatogenic tissue, central nervous system, T and B cells 
33,34. 
The overexpression of MYB gene had been reported to be associated with leukemias, 
lymphomas, pancreatic, colon and breast tumors and the disruption of MYBL1 expression leads 
to defects in the tissues where it is expressed that may be involved in tumorigenesis 33,34. 
In their series of pediatric gliomas, Tatevossian, et al (2010)14 and Zhang, et al (2013)3 
verified that MYB abnormalities at a genomic level, such as, MYB amplification or MYB 
rearrangements involving fusion with several different genes (ESR1, MAML2, PCDHGA1 and 
QKI), were exclusive of diffuse gliomas, being present in 13%-22% of the cases. Moreover, 
Ramkissoon, et al (2013) 16 demonstrated in their series of diffuse PLGGs that 28% of the diffuse 
astrocytomas presented a partial duplication (of the first 9 exons) of MYBL1 gene that resulted 
in the expression of a truncated MYBL1 protein, without its C-terminal negative regulatory 
domain. However, Zhang et al (2013)3 only described MYBL1 rearrangements in 4.3% of the 
diffuse astrocytomas (one case) of their series of PLGGs.  
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3.2.2 – FGFR1 gene 
The FGFR (Fibroblast Growth Factor Receptors) family consists of four genes encoding 
closely related transmembrane tyrosine kinase receptors, named FGFR1 to FGFR4. The FGFR1 
gene (8p11) encodes the Fibroblast Growth Factor Receptor 1. The FGFR proteins contain in 
their full-length form a hydrophobic leader sequence, three immunoglobulin-like (Ig I, II, and III) 
domains, an acidic box, a transmembrane domain and, a divided tyrosine kinase domain (TKD) 
(Haugsten, Wiedlocha, Olsnes, & Wesche, 2010; Turner & Grose, 2010).  
FGFR1 overexpression has been identified in breast and prostate cancer, being 
associated with tumor progression and poorer prognostic due to cell division, motility, and 
formation of new blood vessels.  
FGFR1 rearrangements and mutations were identified in pediatric gliomas 3,35. According 
with Zhang, et al (2013) 3, the most frequent FGFR1 rearrangement in PLGGs consists in an 
intragenic duplication of the entire FGFR1 region encoding the TKD, resulting in two full-length 
TKDs that lead to FGFR1 autophosporylation (Figure I.5). This rearrangement seemed to be 
exclusive of cerebral diffuse gliomas, being present in 24% of the cases. Zhang, et al (2013) 3 also 
described other FGFR1 rearrangement in PLGGs, that involved fusion with TACC1 and TACC2 
genes, in 2% and 0.7% of the cases, respectively. In their series of pediatric gliomas, Jones et al 
(2013) 35 and Zhang, et al (2013) 3 also reported three FGFR1 missense mutations (N554K, 
V559M, N546K and K656E) occurring in 5% of pilocytic astrocytomas, in 6% of glioblastomas 
harboring the K27M mutations and in one oligoastrocytoma.  
In pediatric gliomas, all of the reported alterations in the FGFR1 gene lead to a 
substantial activation of both MAPK/ERK and PI3K pathways 3,35. 
 
Figure I.5 - FGFR1 rearrangement: TKD duplication. In this figure the wild-type FGFR1 proteins (WT 
FGFR1) are compared with the most frequent FGFR1 rearrangement in PLGG. This rearrangement consists 
in a TKD duplication that results in two full-length TKDs (TKD1 and TKD2) that are separated by a linker 
sequence. This rearrangement leads to FGFR1 autophosphorylation, resulting in the activation of 
MAPK/ERK and PI3K pathways. Adapted from Zhang, et al (2013)3. 
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4 – Pediatric High-grade Gliomas (PHGG) 
Gerges, et al (2013)1 and Yuen and Knoepfler (2013)36 showed that the most common 
and exclusive alterations of PHGGs, occurring in 60-80% of cases, were K27M and G34R/V 
mutations in H3.1 and H3.3 histones. 
The histones H3.1 and H3.3 belong to the histone H3 family. Histone H3 is one of the 
five main histones involved in the chromatin structure of the eukaryotic cells 36,37. However, the 
two variants have distinct functions: while the H3.3 variant is enriched for posttranslational 
modifications associated with active transcription, in the H3.1 variant, marks associated with 
gene silencing are the most common 37. Moreover, while the histone H3.3 is encoded by two 
different genes: H3F3A (1q41) and H3F3B (17q15) and is expressed in a replication-independent 
way 37,38, the histone H3.1 is encoded by several genes (being HIST1H3B gene one of them) and 
is only expressed during the S phase of the cell cycle 37. 
In human gliomas, the K27M mutation (a lysine substitution for a methionine at codon 
27) was reported to occur in H3F3A and HIST1H3B genes, but G34R/V mutations (a glycine 
substitution for an arginine or a valine, at codon 34) were only found in the H3F3A gene. These 
mutations lead to alterations of the N-terminal tail of the histone proteins, a region enriched in 
posttranslational modifications 12,36. The roles of K27M and G34R/V mutations in tumorigenesis 
are independent of each other and occur through different mechanisms (Figure I.6)  36. 
The K27M mutation (in H3.3 and H3.1) is a gain-of-function mutation that leads to a 
global downregulation of the repressive histone mark H3K27me3 and, consequently, to an 
increased acetylation of K27 (K27ac is a histone mark mutually exclusive to K27me3 and 
associated with active transcription) 18,36,38. It is thought that the H3K27M mutant histone binds 
aberrantly to EZH2 (the catalytic subunit of polycomb repressive complex 2 that spreads the 
H3K27me3 mark throughout the genome) and inhibits it enzymatic activity 18,36. In this way, 
reduced H3K27me3 levels and consequent loss of polycomb repressive complex 2 activity could 
be altering specific transcriptional processes within the cell (as gene activation and abnormal 
gene expression) and thus become a driver of gliomagenesis in K27M-mutant PHGG 1,18,36 (see 
Figure I.6). 
The G34R and the G34V mutations (in H3.3) interfere with the activating histone mark 
H3K36me3, leading to an alteration on K36 methylation that is associated with abnormal gene 
expression 1,18. As SETD2 is the only known methyltransferase that catalyzes H3K36me3 in 
humans, it is thought that the H3.3G34R/V mutant histone inhibits its function, leading to a 
consequent decrease in H3K36me3 levels 12. 
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Schwartzentruber, et al (2012)10 and Sturm, et al (2012)11 observed in their series of 
pediatric glioblastomas that the K27M and the G34R/V mutations were heterozygously 
expressed and mutually exclusive in tumors. Moreover, Sturm et al (2012)11 also demonstrated, 
in the same series of pediatric glioblastomas, that the gene expression patterns of the K27M 
mutant tumors closely match with the mid- to late-fetal stages of striatum and thalamus 
development and that the G34R/V mutant signature appears to be most strongly expressed in 
early embryonic regions and early- to mid-fetal stages of neocortex and striatum development, 
possibly indicating different cellular origins and/or time of tumor initiation for these two 
subgroups. In fact, these histone mutations were shown to have different distributions 
according to the brain region and patients’ age: while H3.1 K27M mutation appears to be 
restricted to diffuse infantile pontine gliomas and non-brainstem pediatric glioblastomas in a 
younger range of patients (median age of 4.75 years) 12,13; H3.3 K27M mutations are specific of 
tumors with midline locations (thalamus, pons and spinal cord) of patients with a median age of 
10.5 years and; H3.3 G34R/V mutations were only observed in the cerebral cortex of older 
children and adolescents (median age of 18 years) 10,11 (Figure I.6). The comparison of the 
patients’ overall survival also showed that the patients with gliomas harboring the K27M 
mutation had a shorter survival time and consequently a worse prognostic, relatively to the 
patients with G34R/V-mutant gliomas 11 (Figure I.6). 
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Other genetic alterations have been identified in pediatric and adult glioblastomas, such 
as alterations in PDGFRA, EGFR, IDH1 and IDH2 genes. Thus, seven biologic subgroups of 
pediatric and adult glioblastomas were identified based on specific molecular-genetic 
alterations and key clinical parameters, which are the following: K27 (characterized by the K27M 
mutation), G34 (characterized by the G34R/V mutations), PXA-like (characterized by the 
BRAFV600E mutation and CDKN2A homozygous deletion), RTK-I (enriched for PDGFRA 
amplification and CDKN2A gene deletion), RTK-II (associated with EGFR gene amplification and 
CDKN2A gene deletion) Mesenchymal (characterized by low incidence of copy-number changes 
and no characteristic point mutation) and IDH (associated with mutations in IDH1 and IDH2 
genes). While the K27, the G34 and the PXA-like subgroups are exclusive of the pediatric 
population, the RTK-II subgroup was only identified in adult patients and the RTK-I, the 
Mesenchymal and the IDH subgroups were identified in both adult and pediatric populations. 
Moreover, the patients’ overall survival seems to be longer in PXA-like, IDH1 and G34 subgroups 
when compared with K27, RTK-I, RTK-II and Mesenchymal subgroups. All glioblastomas 
subgroups, except the K27, are associated with hemispheric locations 11,18,28,29. 
Figure I.6 - Distribution and Characteristics of H3.3-Mutated Gliomas. G34R/V mutations 
(gray, top) in H3F3A gene are located, primarily, in the cerebral hemispheres of older children and 
adolescents (median age 18 years) and appear to affect K36me3 levels, possibly through inhibition of 
the methyltransferase SETD2. K27M mutations (pink, down) in the H3F3A gene are found, primarily 
in midline locations (spinal cord, thalamus, pons and brainstem) of child patients (median age 10.5 
years) and seem to attenuate the EZH2 methyltransferase function, decreasing global K27me3 levels. 
Moreover, the K27M mutation is associated with a shorter overall survival time when compared to 
the G34R/V mutations. Adapted from Yuen & Knoepfler (2013)36 and Schwartzentruber, et al (2012)10. 
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II - Objectives: 
 
The aims of the current study were fundamentally two: 
1) To establish the genetic profiling by investigating the frequency of alterations in the BRAF, 
MYB, MYBL1, FGFR1, CDKN2A, H3F3A, H3F3B and HIST1H3I genes in pediatric gliomas; to 
correlate them with clinical features, such as: patients’ gender, age at time of surgery, outcome 
and tumors’ location and histological classification and to discuss our findings in order to better 
stratify tumors and treatments  
2) To analyze the aforementioned genetic alterations in cell lines established from pediatric 
brain tumors at the laboratory, aiming that these cell lines offer findings that may pave the way 
into the development of more efficient therapies for pediatric gliomas. 
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III - Materials and Methods: 
The present work can be divided into three major experimental stages: the first is a 
fluorescent in situ hybridization (FISH) analysis (in fresh and paraffin embedded material), the 
second is sequencing using Sanger methodology (in fresh and paraffin embedded material), and 
the third, cell culture (from fresh material). 
While FISH analysis was used to identify the BRAF/KIAA1549 rearrangement and fusion, 
MYB, MYBL1 and FGFR1 rearrangements and CDKN2A deletion; sequencing (using Sanger 
methodology) was used to identify single point mutations in BRAF, H3F3A, H3F3B and HIST1H3I 
genes. Cell culture was used to establish cell lines from tumors (see Figure III.1). 
 
 
 
Figure III.1 – Schematic representation of the experimental work. Tumor samples were received as fresh material or 
embedded in paraffin, normally 10 cuts of 10µm and 3 cuts of 50µm or as 4µm cut on a glass slide. The experimental work 
was divided into three stages: (1) FISH (in fresh and paraffin embedded material) to analyze gene rearrangements; (2) 
Sequencing using Sanger methodology to analyze gene mutations; and (3) Cell culture (from fresh material) to establish cell 
lines from tumors. 
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1 – Biological Material – Patients Samples  
In the context of this thesis, samples were studied from pediatric gliomas referred to 
the IPOFG from 1992 to 2015. Tumor samples were received as fresh material or embedded in 
paraffin, normally 10 cuts of 10µm and 3 cuts of 50µm or as 4µm cut on a glass slide. 
In total, 109 pediatric gliomas were studied for genetic alterations: 67 (61.5%) grade I 
gliomas, 13 (11.5%) grade II gliomas, 14 (12.8%) grade III gliomas, 8 (7.3%) grade IV gliomas and 
7 (6.4%) not otherwise specified (NOS) gliomas (Figure III.2). The following variables were 
collected:  patient’s gender, patient’s age at the time of tumor surgery or biopsy, tumor location 
and histological classification.  
 
 
Figure III.2 – Representation of the study population. The graphic “Study Population” (on top) 
represents all the studied gliomas (in the context of this work) by WHO Grades. In this graphic, NOS (in 
purple) represents the group of the Not-Otherwise Specified Gliomas. Each one of the remaining four 
graphics (Grade I Gliomas, Grade II Gliomas, Grade III Gliomas and Grade IV Gliomas) represents the 
histological subgroups within each WHO grade. The number of gliomas studied is represented between 
brackets in each graphic.  
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Due to the lack of biological material or quality of the results, not all genes were analyzed 
in all samples. 
Although posterior fossa gliomas normally include brainstem and cerebellum gliomas, 
for research purposes a subdivision in three groups was done based on the location of the 
glioma: cerebellum, brainstem and, when no further information was obtained, posterior fossa. 
2 – Fluorescent In Situ Hybridization (FISH) 
 FISH is a cytogenetic technique in which a specific short strand of DNA labeled with a 
fluorescent dye (DNA probe) is used to detect genetic abnormalities in a target DNA sequence. 
Thus, FISH is based on the inherent organization of DNA into two antiparallel complementary 
strands: after denaturation of target DNA, single-stranded DNA probes are allowed to form 
hybrid double-stranded complexes with their complementary genomic sequence. FISH probes 
can be directly labelled with the incorporation of a fluorophore or indirectly labelled with the 
incorporation of a  non-fluorescent hapten or molecule that uses an enzymatic or immunological 
detection system 39. The principles of FISH are represented in Figure III.3. 
 
One of the most important considerations in FISH analysis is the choice of probe. There 
are three main types of probes, each with a different range of applications: whole-chromosome 
painting probes (mainly used in the identification of both numerical and structural chromosome 
aberrations in metaphase spreads), repetitive sequence or enumeration probes (mainly used as 
centromeric-specific probes to detect aneuploidies), and locus-specific probes (which are 
usually genomic clones used to detect structural rearrangements) 40,41. 
Figure III.3 – The Principles of FISH. In FISH technique, a DNA probe (blue) is directly or indirectly 
labelled with a fluorescent dye (red). The labelled probe and the target DNA are then denatured and 
hybridized which allows the detection of the probe signal by a fluorescent microscope. Available in: 
http://www.abnova.com /support/resources.asp?switchfunctionid=%7BB4285500-DB85-435D-BE02-
2BF420D5C70D%7D 
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 FISH enables a multicolor detection of simultaneously hybridized probes. So, beyond 
single signal probes, dual-color probes are broadly used as dual fusion (translocation) probes, 
break apart (“split-apart” rearrangement) probes, and deletion detection probes. In a dual 
fusion probe, each gene involved in a translocation is labelled in a different color (normally, red 
and green) and a juxtaposition of the genes (due to the translocation) results in a fusion signal 
(yellow). A break apart probe consists of sequences flanking the target gene causing the 5’ and 
3’ portions of the gene, to be labeled in different colors (normally, red and green). Thus, a 
separation of the different colored signals, is observed when a translocation or a rearrangement 
occurs. In a deletion detection probe a locus-specific probe is used in conjunction with an 
enumeration probe 40,41. 
 In the present work, the FISH technique was performed in interphase nuclei with DNA 
probes indirectly labelled. These probes are labelled with biotine or digoxigenin that are then 
detected with specific antibodies: streptavidin combined with cyanine 3 (Cy3) fluorophore 
(Jackson ImmunoResearch Laboratories) and anti-digoxigenin-fluorescein (Roche), respectively. 
Cy3 is detected in the red spectrum, while fluorescein is observed in the green spectrum, 
thereby being detectable under a fluorescence microscope through a red and a green filter, 
respectively (Table III.1). 
The BRAF/KIAA1549 rearrangement was studied by FISH with a dual fusion probe in which 
the BRAF gene was labeled in red and the KIAA1549 gene was labelled in green (see table III.1), 
as well as with an enumeration probe directed against the centromeric region of chromosome 
7. Break apart probes were used to study MYB, MYBL1, and FGFR1 genes and to study the 
CDKN2A gene; furthermore, a locus-specific probe for the gene and an enumeration probe for 
chromosome 9 were used (see table III.1). 
2.1 – DNA Probes Preparation 
To label the DNA probes a commercial kit was used: the BioPrime® DNA Labeling System. 
The principle of this technique is to incorporate the biotin (or digoxigenin) into nucleic acid 
probes, which will be detected by anti-biotin or anti-digoxigenin antibodies, respectively.  So, 
random primers (octamers) are annealed to the denatured DNA template and extended by 
Klenow fragment (large fragment of DNA polymerase I) in the presence of biotin or digoxigenin, 
to produce sensitive biotinylated or digoxigenin labeled-DNA probes for use. With this kit, a DNA 
synthesis occurs, resulting in a 10-40 fold amplification of the probe. To separate unincorporated 
nucleotides from the labelled probes, an ethanol precipitation was used. The probes were then 
dissolved in TE (DNA Hydration Solution, Citogene) and stored at -20°C. Labelled DNA was 
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precipitated in the presence of Human Cot-1 DNA® or UltraPure™ Salmon Sperm DNA Solution 
(for centromeric probes), as both block non-specific hybridization. A FISH protocol was used for 
metaphases from a normal human donor peripheral blood to confirm labelled probes specificity. 
Table III.1 – Probes used for FISH and their characteristics. Descriptive table of the probes used in 
FISH analysis. Each column represents a probe characteristic: name, type, localization and application, 
and the label used.  
Gene Name Type 
Chromosomic Localization and 
Application 
Label 
BRAF 
RP4-592P3  Dual Fusion  
7q34. To detect the 
BRAF/KIAA1549 fusion 
Biotine (red) 
RP4-726N20  Dual Fusion  
7q34. To detect the 
BRAF/KIAA1549 fusion 
Biotine (red) 
KIAA1549 RP11-148L5  Dual Fusion  
7q34. To detect the 
BRAF/KIAA1549 fusion 
Digoxigenin 
(green) 
MYB 
RP11-63K22  Break Apart 
6q23.3 (5’ gene portion). To 
detect gene rearrangements 
Biotine (red) 
RP11-170P19  Break Apart 
6q23.3 (3’ gene portion). To 
detect gene rearrangements 
Digoxigenin 
(green) 
MYBL1  
RP11-117K19  Break Apart 
8q13.1 (5’ gene portion). To 
detect gene rearrangements 
Biotine (red) 
RP11-110J18  Break Apart 
8q13.1 (3’ gene portion). To 
detect gene rearrangements 
Digoxigenin 
(green) 
FGFR1  
RP11-118H9  Break Apart 
8p11.23 (5’ gene portion). To 
detect gene rearrangements 
Digoxigenin 
(green) 
RP11-246A12  Break Apart 
8p11.23 (3’ gene portion). To 
detect gene rearrangements 
Biotine (red) 
CDKN2A RP11-149I2  Single signal 
9p21.3. To detect gene 
deletions 
Digoxigenin 
(green) 
Centromere of 
chromosome 7 
(CEP 7) 
pZ7.5 Enumeration 
Centromeric region of CEP 7. To 
detect chromosome deletions 
Biotine (red) 
Centromere of 
chromosome 9 
(CEP 9) 
pMR9A Enumeration 
Centromeric region of CEP 9. To 
detect chromosome deletions 
Biotine (red) 
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2.2 - The FISH Methodology: 
FISH techniques were performed in our series of cases as represented in Figure III.4. 
2.2.1 - Nuclei Extraction from paraffin embedded material: 
Nuclei extraction was done in paraffin embedded material (cuts of 50µm). This 
procedure consisted in a tissue de-paraffination, in which paraffin was dissolved at room 
temperature with three 10 min changes of xylene. Then, to digest the cytoplasm and set the 
nuclei free, paraffin sections were treated with protease (P8038-100MG, Sigma-Aldrich; 100µl 
protease/1ml Carlsberg solution) for 1 hour at 37°C. This enzymatic digestion was accompanied 
by a mechanical digestion and was stopped with ice cold (4°C) PBS. Free nuclei were then 
Figure III.4 – Schematic representation of the FISH methodology. The FISH technique was performed in 
fresh tumor material, paraffin embedded tumor material (cuts of 50µm and sections of 4µm on glass slide). First 
it was necessary to obtain nuclei from paraffin embedded material (nuclei extraction) and from fresh material 
(imprint). Paraffin sections of 4µm on glass slide were ready to use. A glass slide de-paraffinization was done in the 
paraffin embedded material. Five steps were then performed: Pre-treatment of glass slides, heat denaturation of 
target DNA and probe, Post-hybridization washes, Probe detection, and FISH analysis.   
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submitted to a fixation process which consisted in the destruction of non-nuclear material by 
nuclei resuspension in a freshly prepared fixative (three parts methanol and one part glacial 
acetic acid). The resulting fixed nuclei suspension was spread on a glass slide (Appendix 1). 
2.2.2 – Imprint preparation from fresh material 
An imprint consists in touching the tumor fragment gently on a glass slide. After a 30min 
drying period at room temperature, glass slides were submitted to a hypotonic solution (NaCl 
0.2%), which caused cellular membrane rupture and cellular lysis. Then, nuclei were submitted 
to a fixation process, to destroy non-nuclear material, by using a freshly prepared fixative (three 
parts methanol and one part glacial acetic acid).  
2.2.3 – Glass slide de-paraffinization  
This procedure was only done to glass slides from paraffin embedded material (10µm) 
and paraffin sections (4µm) in glass slide. It is an incubation in xylene and 100% ethanol for 
30min each. 
2.2.4 – Pre-treatments of glass slides 
Pre-treatments of glass slides consisted in cell permeabilization with the purpose of 
making the target DNA (from the tumor) accessible for probe binding. This was accomplished 
with 2xSSC washes at different temperatures (5min at 37˚C, 30min at 75˚C, 3min at 37˚C) for 
imprints and nuclei from embedded paraffin material; with Juice (citrate buffer, 1x at 90°C for 
17 min) for 4µm paraffin sections; and with enzymatic reactions, which digest the proteins that 
surround the nucleus: Proteinase K (P6556-100MG, Sigma-Aldrich) for nuclei from embedded 
paraffin material (10min) and Pepsin (P7000-100G, Sigma-Aldrich) for imprints and sections in 
glass slide (5-10min and 45min, respectively). Enzymatic reactions were stopped with ice cold 
(4˚C) PBS. At room temperature, glass slides were washed in PBS for 5 min and incubated in a 
Buffer Solution (5ml MgCl2 with 95ml PBS). Subsequently they were submitted to a Fixation 
Solution (5ml MgCl2, 3,7ml of Formaldehyde and 91.3ml of PBS). Finally, glass slides were 
dehydrated and air dried. (Appendix 1).  
2.2.5 – Conjunction heat denaturation of target DNA and probe 
The specific probe, diluted in hybridization solution, was added to the nuclei area in the 
glass slides and co-denatured with sample DNA: 5min at 90°C for nuclei from paraffin embedded 
material, 5min at 75°C for imprints, and 15min at 85°C for 4µm sections in glass slide.  After 
denaturation, glass slides were stored for 16h at 37°C in a moist chamber for hybridization. 
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2.2.6 – Post-Hybridization Washes 
 Post-hybridization washes remove residual probe and unspecific bindings that interfere 
with the hybridization signal and are performed by first immerging glass slides for 15min, in a 
50% of formamide solution at 42-43˚C  and, then, in a 2xSSC solution with Tween 20 at 42-43˚C.  
2.2.7 – Probe detection 
The probes used in the present work were indirectly labelled. So, after post-
hybridization washes, two incubation steps were performed: in the first incubation, TNB 
(Blocking Reagent, Roche) was used (10min at room temperature) to bind to nonspecific 
sequences and decrease background; the second incubation (30min at 37°C) was done with 
specific antibodies: Streptavidin conjugated with Cy3 fluorophore (Jackson ImmunoResearch 
Laboratories) and anti-digoxigenin-fluorecein (Roche), for biotine and digoxigenin labeled 
probes (respectively). To avoid unspecific bindings, antibodies were diluted in TNB in a 
proportion of 1:300 for streptavidin conjugated with Cy3 fluorophore and 1:100 for anti-
digoxigenin-fluorecein. To remove residual antibodies, glass slides were washed twice in TNB 
buffer, with agitation. After being dehydrated, glass slides were air dried and mounted in 
VECTASHIELD® Mounting Medium with DAPI (4’,6-diamidino-2-phenylindole). DAPI is a nuclear 
counterstain, it is observed in the blue spectrum, thereby being detectable under a fluorescence 
microscope through a blue/cyan filter. Glass slides were stored in the dark at 4°C.  
2.2.8 – FISH analysis 
FISH analysis was performed under a fluorescence microscope linked to a CytoVision® 
software (Applied Imaging, UK). FISH analysis was performed by counting at least 100 cells per 
slide with intact, non-overlapping nuclei taken from different randomly chosen fields of view. 
The counted scores were expressed as percentage value, using a minimum cutoff level of 10% 
to define significant cell clone. 
 
3 – Sequencing using Sanger Methodology:  
DNA sequencing allows nucleotide sequence determination. This technique is based on 
Sanger’s methodology, where there is a selective incorporation of chain-terminating 
dideoxynucleotides (ddNTPs: modified dNTPs that lack a 3’-OH group, required for the formation 
of a phosphodiester bond between two nucleotides, causing DNA polymerase to cease 
extension of DNA when a modified ddNTP is incorporated) by DNA polymerase during in vitro 
DNA replication. Each ddNTP is labelled with a different color fluorophore to differentiate the 
four nitrogenous bases (adenine, guanine, cytosine and thymine) 41. 
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In the context of this work, sequencing using Sanger methodology was used to identify 
single point mutations in four specific genes: BRAF, H3F3A, H3F3B and HIST1H3I genes. DNA for 
gene analysis was extracted by different procedures according to the material used (as described 
in sections 3.1, 3.2, and 3.3). Target genes amplification was achieved through polymerase chain 
reaction (PCR), as described in section 3.5. 
3.1 – DNA extraction from paraffin embedded material 
The protocol used was adapted from Imyanitov, et al (2001), BioTechniques42. This 
procedure briefly consisted in a tissue de-paraffinization, where 10µm sections of paraffin 
embedded material were incubated in xylene and ethanol for 30min each. To permeabilize 
nuclei Proteinase K (P6556-100MG, Sigma-Aldrich) was used. The extracted DNA was diluted in 
chelating resin Chelex (Instagene matrix BIO-RAD) and precipitated with sodium acetate (3M 
NaAc, pH 5.2) and 100% ethanol. For mutation analysis DNA was dissolved in TE (DNA Hydration 
Solution, Citogene). 
3.2 – DNA extraction from fresh material  
The first step was a mechanical digestion of the tumor fragment. Then, a chemical 
disintegration was done with Buffer Lysis, SDS 10% and Proteinase K (P6556, Sigma-Aldrich), for 
2-3 hours at 56°C. These three reagents provoke cellular lysis, lipids dissolution and proteins 
digestion. Acid nucleic extraction from the tumor fragment was done through the phenol-
chloroform method. These two reagents denature proteins, rendering them solubilized in the 
phenolic phase. The latter is efficiently separated from the aqueous phase, where the DNA is. 
DNA precipitation was done with sodium acetate (3M NaAc, pH 5.2) and 100% ethanol. It was 
then dissolved in TE (DNA Hydration Solution, Citogene). 
3.3 – DNA extraction from cell culture 
The protocol used was adapted from the Citogene® DNA cell and tissue kit. The obtained 
DNA was precipitated with isopropanol and then dissolved in TE (DNA Hydration Solution, 
Citogene). 
3.4 – DNA quantification 
Quantification of DNA re-suspended in TE (DNA Hydration Solution, Citogene) was done 
using NanoDrop 2000 (Thermo Scientific) spectrophotometer. For gene analysis, DNA was 
diluted to 80ng/µl. 
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3.5 – Polymerase Chain Reaction (PCR) 
PCR is an enzymatic technique that allows in vitro amplification of DNA fragments. This 
process involves three main steps that are repeated in various cycles, normally between 30-40 
cycles: target DNA denaturation (at 95°C), annealing (primers bind to their complementary 
sequences) and enlongation (polymerase synthesizes a new DNA chain in the presence of 
magnesium ions – Mg2+ – and deoxynucleotides – dNTP’s). Primers used in the PCR reactions are 
those described in Table III.2. All PCR reactions were done in a termocycler Veriti (Applied 
Biosystems), using the programs in Figure III.5.  
 
Figure III.5 - Programs used for PCR amplification of BRAF, H3F3A, H3F3B and 
HIST1H3I genes. The DNA denaturation step was performed at 95°C. The temperature used 
for the annealing step was different for each gene: 58°C, 61.5°C and 63°C for BRAF, H3F3A, 
H3F3B and HIST1H3I genes (respectively). For the enlongation step the temperature used was 
72°C for all genes. The time of each step is represented in seconds (sec) and minutes (min). The 
number of cycles were 40 for BRAF gene and 35 for H3F3A, H3F3B and HIST1H3I genes. The 
reactions stopped at 4°C. 
Table III.2 – Primers used for each gene PCR reaction. Representation of the primers used 
in PCR for the genes analyzed: BRAF, H3F3A, H3F3B and HIST1H3I 
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The PCR reaction efficiency was controlled through an agarose gel 2% (p/v) horizontal 
electrophorese. Each PCR product was enzymatic purified, using Exonuclease I (20U/μl Thermo 
Scientific) and a Thermosensitive Alkaline Phosphatase (FastAP: 1U/µl Thermo Scientific). After 
purification, PCR products were amplified by PCR with ddNTP labelled with different color 
fluorophores, using the conditions described in Figure III.6. These second PCR products were 
then purified and precipitated with a reactional mixture with EDTA (125mM) that chelates Mg2+ 
ions, and sodium acetate (3M, pH 4.6) that neutralizes nucleic acids charges. 
3.6 – Sequencing 
To sequence samples, an automatic sequencer, ABI PrismTM 3130 Genetic Analyser 
(Applied Biosystems), was used, where capillary electrophorese occurred at 50°C and 15KV. 
Electrophoretograms were compared with the reference DNA sequence for the gene being 
studied to identify the presence or absence of mutations. Reference DNA sequences were 
obtained from Ensembl data base, available from: http://www.ensembl.org/index.html. 
Figure III.6 – Programs used for sequencing reactions of BRAF, H3F3A, H3F3B and HIST1H3I 
genes. The DNA denaturation step was performed at 95°C. The temperature used for the 
hybridization step was different for each gene: 59.5°C, 61.5°C and 63°C for BRAF, H3F3A, H3F3B and 
HIST1H3I genes (respectively). For the extension step the temperature used was 60°C for all genes. 
The time of each step is represented in seconds (sec) and minutes (min). The number of cycles were 
25 for all genes. The reactions stopped at 4°C. 
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4 – Establishment of cell lines from tumors  
Cell lines were established from tumor fragments at the laboratory. All the procedures 
were done in a laminar flow hood to guarantee sterile conditions. 
First, the tumor fragment was mechanically disintegrated. The disintegrated tumor 
fragment was incubated at 37°C, in a moist 5% CO2 environment, with collagenase the necessary 
time to achieve a complete dissociation of the tumor cells without plasmatic membrane 
destruction. The dissociation level was analyzed through an inverted microscope. The 
disintegrated material was then washed with RPMI 17% and centrifuged twice, at 2400rpm for 
2min, in order to remove death cells and cellular debris. Tumor cells were then diluted in CNS 
tumors medium with 10% fetal bovine serum (FBS) and transferred to a culture flask (T25cm2). 
At the end, there should have been, approximately, 1x105 cells (1ml) per flask.   
Cell cultures were maintained in a moist 5% CO2 environment to preserve the neutral 
and stable pH. Culture mediums were renewed three times per week to avoid lack of nutrients 
and growth factors. 
When cell cultures were confluent (70-80%), they were subcultured with trypsin in order 
to achieve cellular propagation. A cell line was considered to be established when it had the 
potential to be subcultured indefinitely under appropriate conditions (such as culture medium 
and space). 
5 – Statistical Analyses 
 Statistical Analyses were carried out using GraphPad Prism 5 software (San Diego, USA). 
The two-tailed Fisher’s exact test was used to determine the correlations between the presence 
or absence of genetic alterations and patients’ gender, tumors’ WHO grade, histology and 
location. The unpaired two tailed Student’s t-test was used to study the presence or absence of 
genetic alterations with patient’s age. Survival curves were compared using the Log-Rank 
(Mantel-Cox) test. Differences were considered statistical significant at p-value < 0.05.
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IV – Results: 
 In the present work, 109 pediatric gliomas were analyzed. The figure below (Figure VI.1) represents the summary of the obtained results. 
Figure IV.1 – Summary of the obtained results. Within the group of Grade I gliomas: PA (Pilocytic 
Astrocytoma), GG (Ganglioglioma), DNET (Dysembryoplastic Neuroepithelial Tumor), DIG (Desmoplastic Infantile 
Ganglioglioma), PGT (Papillary Glioneuronal Tumor), GT (Glioneuronal Tumor) SEGA (Subependymal Giant Cell 
Astrocytoma), GC (Gangliocytoma). In grade II gliomas: DA (Diffuse Astrocytoma), O (Oligodendroglioma), PMA 
(Pilomyxoid Astrocytoma); In Grade III Gliomas: AA (Anaplastic Astrocytoma), AO (Anaplastic Oligodendroglioma), 
AOA (Anaplastic Oligoastrocytoma), AG (Anaplastic Ganglioglioma), AGN (Anaplastic Glioneuronal Tumor), X 
(Xanthoastrocytoma); In Grade IV gliomas: GB (Glioblastoma), A (Grade IV Astroblastoma), DIPG (Diffuse Intrinsic 
Pontine Glioma), O (Grade IV Oligodendroglioma); ND (Not Done). Red spots represent the presence of the genetic 
alteration. In the H3F3A row: orange spots – K27M mutation; green spots – G34R mutation; blue spot – G34V 
mutation.  
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1 – BRAF/KIAA1549 rearrangement 
For the BRAF/KIAA1549 rearrangement, 97 pediatric gliomas were analyzed: 60 Grade I, 12 
Grade II, 13 Grade III, 7 Grade IV and 5 NOS. Of these, 27 cases were positive for the 
BRAF/KIAA1549 rearrangement: 22 Grade I Gliomas (21 pilocytic astrocytomas and 1 
glioneuronal tumor), 4 Grade II Gliomas (2 diffuse astrocytomas and 2 pilomyxoid astrocytomas), 
and 1 NOS. None of the PHGG analyzed was positive (Table IV.1). 
 
By using a two-tailed Fisher’s test, the BRAF/KIAA1549 rearrangement was significantly 
correlated with grade I gliomas (p-value=0.0189). Of the grade I gliomas positive for 
BRAF/KIAA1549 rearrangement, all except one (a glioneuronal tumor), were pilocytic 
astrocytomas. This allowed us to conclude that this rearrangement was significantly correlated 
with the histology of pilocytic astrocytoma (p-value<0.0001 when compared with all analyzed 
gliomas and p-value=0.0024 when compared with grade I gliomas).  
The BRAF/KIAA1549 rearrangement was also related with cerebellar locations (two tailed 
Fisher exact test: p-value<0.0001). Moreover, a significant statistic correlation was identified 
between BRAF/KIAA1549-negative cases and cerebral cortex localizations (p-value<0.0001), 
Table IV.1 – Cases studied for BRAF/KIAA1549 rearrangement. The gliomas studied for 
BRAF/KIAA1549 rearrangement are represented in the table above. Each row corresponds to the tumors’ 
histological classification. Each column presents the number of cases and the respective percentage in 
brackets. 
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suggesting that there is a lower probability of this rearrangement to occur in those locations 
(Figure IV.2-A).  
In the cohort of pediatric gliomas under analysis, this genetic rearrangement did not show 
any correlation with the patient’s age or gender (Figure IV.2 – B and C).  
 
  
Figure IV.2 – Summary of the BRAF/KIAA1549 results. (A) BRAF/KIAA1549 vs Location: the 
presence of BRAF/KIAA1549 rearrangement was correlated with cerebellar locations (p-value<0.0001) 
and its absence was correlated with cerebral cortex locations (p-value<0.0001); (B) BRAF/KIAA1549 vs 
Age: BRAF/KIAA1549 rearrangement was not correlated with patients’ age (p-value=0.0573); (C) 
BRAF/KIAA1549 vs Gender: BRAF/KIAA1549 rearrangement was not correlated with patients’ gender 
(p-value=0.3535). 
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2 – BRAF V600E mutation 
In total, 100 pediatric gliomas were analyzed for the BRAFV600E mutation: 61 Grade I 
gliomas, 10 Grade II gliomas, 14 Grade III gliomas, 8 Grade IV gliomas and 7 NOS gliomas (as 
represented in Table IV.2). Of these, 16 cases were positive for the mutation: 9 grade I gliomas 
(6 pilocytic astrocytomas and 3 gangliogliomas), one diffuse astrocytoma, 2 grade III gliomas (1 
anaplastic astrocytoma and 1 xanthoastrocytoma), one astroblastoma, and 3 NOS gliomas.   
 
 
In our series of cases, BRAFV600E mutation did not show any correlation with tumor’s 
WHO grades, histologic subtype and location (p-values>0.05) or with patients’ age (p-
value=0.9253) or gender (p-value=0.2669) (Figure IV.3). 
 
 
Table IV.2 – Cases studied for BRAFV600E mutation. The gliomas studied for BRAFV600E mutation are 
represented in the table above. Each row corresponds to the tumors’ histological classification. Each column 
shows the number of cases and the respective percentage in brackets. 
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3 – MYB, MYBL1 and FGFR1 rearrangement 
For the MYB gene, 80 gliomas were analyzed: 51 Grade I gliomas, 11 Grade II Gliomas, 10 
Grade III gliomas, 7 Grade IV gliomas and 5 NOS gliomas (Figure IV.4).  
Only one glioma (NOS5 – Figure IV.1) was considered to be positive for the MYB gene 
rearrangement, with 25% of cells showing two red signals and one green signal, representing a 
deletion of the 3’ gene portion (see Figure IV.4). 
For the MYBL1 and FGFR1 genes, 79 gliomas were studied: 47 grade I gliomas, 10 grade II 
gliomas, 10 grade III gliomas, 7 grade IV gliomas and 5 NOS. 
Only one glioma (LGG31 – Figure IV.1) was considered to be positive for the MYBL1 gene 
rearrangement, with 12% of cells showing two red signals and three green signals, representing 
a deletion of the 5’ gene portion (see Figure IV.4). However, none of the tumors analyzed for the 
FGFR1 gene was positive for that gene rearrangement. 
Figure IV.3 – Summary of the BRAFV600E results. The presence of BRAFV600E mutation was 
not correlated with (A) tumors’ location, p-values>0.05; (B) patients’ age, p-value=0.9253; (C) 
patients’ gender, p-value=0.2669. 
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4 – CDKN2A deletion 
For CDKN2A gene, 81 gliomas were analyzed: 49 Grade I gliomas, 10 Grade II gliomas, 10 
Grade III gliomas, 7 Grade IV gliomas and 5 NOS gliomas (see Table IV.3). The deletion of the 
CDKN2A oncossupressor gene was identified in 15 cases: 5 grade I gliomas (4 pilocytic 
astrocytomas and 1 subependymal giant cell astrocytoma), 3 grade II gliomas (2 pilomyxoid 
astrocytomas and 1 diffuse astrocytoma), 3 grade IV gliomas (2 astroblastomas and 1 
glioblastoma), and 1 NOS glioma. 
 
 
 
 
Figure IV.4 – Summary of the MYB, MYBL1 and FGFR1 results. (A) The gliomas studied for MYB, MYBL1 
and FGFR1 genes are represented in the table above. Each row corresponds to the tumors’ WHO grade. Each 
column shows the number of cases and the respective percentage in brackets. (B) FISH images using probes 
corresponding to sequences immediately distal (red) and proximal (green) of MYB 1) MYB rearrangement; 2) 
Copy Neutral; 3) MYB gain. (C) FISH images, using probes corresponding to sequences immediately distal (green) 
and proximal (red) of MYBL1: 1) MYBL1 rearrangement; 2) Copy Neutral; 3) MYBL1 gain. (D) FISH images using 
probes corresponding to sequences immediately distal (red) and proximal (green) of FGFR1: 1) FGFR1 gain; 2) 
Copy Neutral. 
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Results showed that the incidence of CDKN2A deletion tended to increase with the tumors’ 
WHO grade: 10% in grade I gliomas, 30% in grade II and III gliomas and 42.9% in grade IV gliomas. 
However, the two-tailed Fisher’s test used, only allowed for identification of a statistical 
significant correlation between grade I gliomas and the absence of this genetic deletion (p-
value= 0.0219). 
Although CDKN2A deletion did not correlates with tumor location (p-values>0.05), patients’ 
age (p-value=0.5985) or gender (p-value=1) (Figure IV.5), it correlated with the histology of 
glioblastomas (Table IV.3). However, this correlation was only observed when glioblastomas 
were compared with all gliomas (p-value=0.0189). When glioblastomas were compared with 
grade IV gliomas this correlation was not significant (p-value=0.1429), which may be explain by 
the small sample size (7 cases). 
Table IV.3 – Cases studied for CDKN2A gene deletion. The gliomas studied for CDKN2A deletion are 
represented in this table. Each row corresponds to the tumors’ histological classification. Each column 
shows the number of cases and the respective percentage in brackets. 
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All CDKN2A deletions in PLGG were heterozygous and also presented a chromosome 9 
centromeric region deletion. This suggested that a complete loss of chromosome 9 or at least of 
the 9p arm occurred in these cases, rather than a specific gene deletion. In PHGG, 3 cases had a 
homozygous CDKN2A deletion without loss of chromosome 9 suggesting that in these cases a 
specific deletion of CDKN2A region occurred (Appendix 2). 
 
5 – Histone genes mutations  
Exon 1 was studied in the three histone genes (H3F3A, H3F3B and HIST1H3I) to search for 
mutations at codons 27, 34 and 36. The K27M mutation was identified in 4 cases. At codon 34, 
the G34R mutation was identified in 2 cases and the G34V mutation in 1 case. These mutations 
were only observed in the H3F3A gene and in PHGG. No alterations were seen at codon 36 in 
the three genes studied. The obtained results are depicted in Figure IV.6. 
Figure IV.5 – Summary of the CDKN2A results. The CDKN2A gene deletion was not correlated 
with (A) tumors’ location (p-values>0.05); (B) patients’ age, p-value=0.5985; (C) patients’ gender, p-
value=1. 
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All H3F3A-K27M mutations (n=4) were identified in tumors located in the brainstem, 
while all H3F3A-G34R mutations (n=2) occurred in tumors located in the cerebral cortex (Figure 
IV.1). By using a Student t test, one could observe that H3F3A mutations were correlated with 
patients’ age (p-value=0.0088): K27M mutations occurred in younger children (mean=7.5 years) 
and G34R/V mutations occurred in older children (mean=13 years), as represented in Figure 
IV.7. The presence of H3F3A mutations was not correlated with patients’ gender, p-
value=0.0877 (Figure IV.7). 
 
 
 
 
Figure IV.6 – Summary of the histone genes results. (A) The gliomas studied for H3F3A, H3F3B and HIST1H3I 
genes are represented in the table above. Each row corresponds to the tumors’ WHO grade. Each column shows 
the number of cases and the respective percentage in brackets. (B) Comparison of Sanger sequencing 
chromatograms of wild-type H3F3A gene and H3F3A-K27M mutation: substitution of an adenine for a thymine 
that results in the substitution of amino acid lysine for the amino acid methionine, at codon 27. (C) Comparison 
of Sanger sequencing chromatograms of wild-type H3F3A gene and H3F3A-G34R and H3F3A-G34V mutations: in 
G34R there is a substitution of a guanine for an adenine, resulting in a glycine substitution for an arginine; in G34V 
the substitution is between a guanine and a thymine, resulting in the amino acid valine instead of glycine. 
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6 – Tumor recurrences 
Of the 109 gliomas studied, 14 were primary tumors that recurred and 9 gliomas were 
recurrences (secondary tumors). However, only in 8 cases both the primary and the recurrence 
were evaluated, as represented in Figure IV.8. 
Figure IV.7 – Summary of the H3F3A results in PHGG. The graphic on the left shows that, in PHGG, 
the H3F3A-G34R/V mutant tumors tended to appear in older children, while H3F3A-K27M mutant tumors 
tended to appear in younger children (p-value=0.0088). The graphic of the right shows that, in PHGG, the 
H3F3A mutations were not correlated with the patients’ gender (p-value=0.0877). 
Figure IV.8 – Summary of the tumor recurrences. The cases are 
grouped, in each group, the first case corresponds to the primary tumor 
and the second case to the secondary glioma. Within the group of Grade I 
gliomas: PA (Pilocytic Astrocytoma), GG (Ganglioglioma), in grade II 
gliomas: DA (Diffuse Astrocytoma), O (Oligodendroglioma); In Grade III 
Gliomas: AA (Anaplastic Astrocytoma), AO (Anaplastic Oligodendroglioma) 
and in Grade IV gliomas: GB (Glioblastoma). ND (Not Done). Red spots 
represent the presence of the genetic alteration. . In the H3F3A row: 
orange spots – K27M mutation; green spots – G34R mutation; blue spot – 
G34V mutation. 
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The 14 primary tumors that recurred were compared with the remaining study population 
(excluding the secondary tumors) and the only statistically significant correlation found was 
between recurrence and loss of the CDKN2A gene (p-value=0.0149). The same procedure was 
done for secondary tumors, but no correlations were found between these and the studied 
variables (Figure IV.9).  
 
7 – Cell Line 
A cell line was established from a high-grade tumor (HGG14 – Figure IV.1) from a 14 
year-old male child. The case was classified as a WHO grade III xanthoastrocytoma and was 
located in the cerebral cortex. Among the panel of genes evaluated in this study the only genetic 
alteration identified in this case was a BRAFV600E mutation.  
Figure IV.9 – Summary of the tumor recurrences results. (A) The primary tumors that did not 
recur, the primary tumors that recurred and the secondary tumors, are represented in the table 
above. Each row corresponds to the studied genes. Each column shows the number of cases and the 
respective percentage in brackets (B) The CDKN2A gene deletion was related with the primary tumors 
that recurred (p-value=0.0149).  
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8 – Survival Curves 
Survival curves were drawn for the different genetic alterations by using the Kaplan-
Meier test. No statistical significant differences in patients’ survival curves were observed for 
BRAF/KIAA1549 rearrangement (p-value= 0.5224), CDKN2A deletion (p-value= 0.2286) or 
between the K27M and the G34R/V H3F3A mutations (p-value= 0.4795). However, the presence 
of the BRAF mutation seemed to be associated (p-value=0.0443) to a better overall survival rate, 
when compared with its absence (see Figure IV.10). Moreover, the K27M mutation in histone 
H3F3A was associated with a worse overall survival curve, when compared with patients with 
H3F3A wild-type gliomas, p-value= 0.0255 (see Figure IV.11).  
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Figure IV.10 – BRAFV600E: Survival proportions. There is a statistical significant difference between the 
two survival curves (tumors not harboring the BRAF mutation and tumors with the mutation), with a p-
value= 0.0443. 
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Figure IV.11 – H3F3A mutations: Survival Proportions. This graphic represents three survival curves: 
one for wild-type H3F3A gliomas, one for K27M-mutant gliomas and another for G34R/V-mutant tumors. 
The only statistically significant difference found between these curves was between the wild-type and 
the K27M curves (p-value= 0.0255) 
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V – Discussion: 
 
1 – Study Population 
As was to be expected from previous similar studies 1,3,43, in the glioma cohort analyzed, 
the most frequent were pilocytic astrocytomas (44.9%) and the less common were 
oligoastrocytic tumors (0.9%). 
  However, the incidences of glioblastomas and diffuse astrocytomas, in the analyzed 
cohort of gliomas, 3.7% and 4.6%, respectively, were lower than the ones described in previous 
literature: 6.3% and 11.1%, respectively. Furthermore, the incidences of anaplastic 
astrocytomas and oligodendrogliomas – 5.5% for both, in the study population – were higher 
than expected – 3.6% and 2.5%, respectively 43. This difference between the incidences of each 
tumor histological subtype may be explained due to disparities in pediatric CNS tumors 
incidence among different countries 44. 
In the present work, 109 pediatric gliomas were analyzed. This represents a robust 
population of a rare tumor entity and it was the first time that the genetic profile of pediatric 
gliomas was determine in the Portuguese population. 
2 – BRAF gene alterations 
The BRAF/KIAA1549 rearrangement has been described as a driver genetic event in 
pilocytic astrocytomas, rarely detected in other gliomas and extremely rare in PHGG 5,6. Our 
results corroborate this finding: the majority of the cases positive for the BRAF/KIAA1549 
rearrangement were pilocytic astrocytomas (77.8%) and none were PHGGs. Although 
BRAF/KIAA1549 rearrangement was tightly correlated with pilocytic astrocytoma morphology in 
the studied cohort of gliomas (p-value<0.0001), it was not exclusive of this histological subtype. 
The BRAF/KIAA1549 rearrangement was further identified in other PLGGs, such as: glioneuronal 
tumors, diffuse astrocytomas and pilomyxoid astrocytomas. The frequencies of the 
BRAF/KIAA1549 rearrangement in these histologic subtypes (50%, 50% and 100%, respectively) 
were higher than expected 5,7. These results may be explained by the small sample size for each 
histological subgroup.  Moreover and in accordance with Horbinski (2013)5, results also show 
that the presence of the BRAF/KIAA1549 rearrangement correlates with cerebellar tumors 
locations (p-value<0.0001) and its absence correlates with cerebral cortex tumors locations (p-
value<0.0001). 
In the studied glioma cohort, the BRAFV600E mutation did not show any statistical 
significant correlation with the tumors’ WHO grades, histologic subtypes, patients’ age or 
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gender. Our data is in line with the results of Schindler, et al (2011) 4 and Zhang, et al (2013) 3 
since the BRAFV600E mutation, in our study, was identified in 43% of the gangliogliomas, in 33% 
of the diffuse astrocytomas and in 13% of the pilocytic astrocytomas. Although Korshunov, et al 
(2015) 28 had shown that BRAFV600E mutation was present in 10% of the glioblastomas, in our 
cohort of gliomas no glioblastoma showed this mutation. These results may be connected to the 
fact that only 4 glioblastomas were analyzed. Moreover, our data also show that the 
BRAFV600E-positive gliomas have a statistical significant (p-value=0.0443) longer overall survival 
when compared with the gliomas that did not harbor this mutation. A correlation between 
BRAFV600E-postive gliomas and a better prognosis had already been described by Korshunov, 
et al (2015)28 and Mistry, et al (2015)30 in different contexts: in PHGGs and in secondary gliomas, 
respectively.  
Accordingly to Horbinski (2013)5 the BRAF mutation and the BRAF/KIAA1549 
rearrangement rarely occur in conjunction in the same tumor. Our results corroborate this 
finding and also show that these two genetic alterations were related with different tumor 
locations: the BRAF/KIAA1549 rearrangement was more common in the cerebellum while the 
BRAFV600E mutation was more common in the cerebral cortex. This is an interesting finding 
because, as it was demonstrated by Horbinski (2013)5, although both BRAF alterations have the 
same effect of turning the B-raf on, leading to MAPK/ERK pathway activation, the tumors that 
harbor either the mutation or the rearrangement have different biologic and clinical behaviors 
5. These differences have great implications for the patients’ treatment because BRAFV600E-
positive tumors are sensible to RAF inhibitors, such as vemurafenib, whereas tumors harboring 
the BRAF/KIAA1549 rearrangement are resistant to it but associated with a favorable response 
to MEK inhibitors, such as selumetinib and trametinib 7,20,25. This implies that, in this context, it 
is important to establish cell cultures from tumors harboring BRAF alterations not only to 
understand the influence of a specific genetic alteration in the tumor behavior at a cellular and 
molecular level, but also to understand how the tumor cells will respond to a specific blockage 
in the context of their other accumulated genetic alterations. In the current work a cell line could 
be established from a tumor harboring the BRAFV600E mutation with the purpose to be used 
for future studies. 
3 – MYB, MYBL1 and FGFR1 rearrangements 
Although Tatevossian, et al (2010)14 showed that an increased nuclear expression of 
MYB was present in diffuse gliomas, pilocytic astrocytomas and PHGG, MYB abnormalities at a 
genomic level, such as genetic rearrangements or amplifications, were only identified in diffuse 
gliomas 3,14. In contrast to these results, in the studied glioma cohort, only one case (NOS5 – 
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Figure IV.1), not classified as a diffuse glioma was considered to be positive for the MYB 
rearrangement. This case showed a 3’ gene portion deletion that had been described as one of 
the two known mechanisms responsible for MYB upregulation in gliomas 14.  
The MYBL1 rearrangement described by Ramkissoon, et al (2013)16 and Zhang, et al 
(2013)3, consisting in a partial duplication of MYBL1 gene giving rise to a truncated protein, was 
not identified in our series of gliomas. However, in the studied cohort of gliomas, a different 
MYBL1 rearrangement, involving a 5’ gene portion deletion, was identified in one pilocytic 
astrocytoma. There is no data in literature showing MYBL1 rearrangements involving 5’ gene 
portion deletion in gliomas. Thus, further studies are needed to verify if the rearrangement 
identified in this cohort of gliomas could lead to oncogenesis.   
Disparities between the results of this study and the data described in literature may be 
explained due to the small size of the diffuse gliomas sample (only 18 diffuse gliomas were 
analyzed) and also to the fact that only few studies in the literature  access the genetic 
alterations of MYB and MYBL1 genes in pediatric gliomas 3,14,16. Thus, further studies are needed 
to better understand the mechanisms leading to MYB upregulation.  
Zhang, et al (2013)3 showed, through whole-genome sequencing, that, although 
relatively infrequent across the entire cohort of low-grade gliomas (7.4%), the FGFR1 duplication 
involving the tyrosine kinase domain was present in 24% of grade II diffuse cerebral gliomas. In 
the studied cohort of gliomas no FGFR1 rearrangements were seen by FISH. Although rare in the 
context of pediatric grade II gliomas, other FGFR1 gene alterations may be linked to oncogenesis, 
as missense mutations and FGFR1 fusions with TACC genes 3. Jones, et al (2013)35 identified the 
presence of FGFR1 mutations in 5% of pilocytic astrocytomas. These FGFR1 mutated-cases were 
BRAF/KIAA1549 negative and had extra-cerebellar locations, mostly in midline locations. In the 
same work, these mutations were also identified in glioblastomas harboring H3F3A gene K27M 
mutation. However, the FGFR1 mutations described by Zhang, et al (2013)3 – N554K and V559M 
– were different from FGFR1 mutations described by Jones, et al (2013)35 – N546K and K656E. 
Thus, it is important to investigate thoroughly the relation between the FGFR1 mutations and 
tumors located in midline. As the FGFR1 gene has an important role in neural stem cell self-
renewal and in midline glial cells development, this spatial clustering may reflect differential 
sensitivity of distinct neuronal precursors to an activating stimuli. Moreover it is important to 
understand how second hits (timing and type) and/or differentiation stage of the cell of origin 
contribute to determine a pilocytic astrocytoma or a glioblastoma formation 35. 
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4 - CDKN2A gene deletion 
Several studies in pediatric gliomas have identified an association between a 
homozygous deletion of the CDKN2A gene with a worst clinical outcome in BRAF-driven gliomas, 
related with a failure to induce senescence or an escape from BRAF-induced tumor senescence 
8,9,30. 
Our results allowed us to conclude that a homozygous or a heterozygous CDKN2A gene 
deletions are associated with tumor recurrences, independently of the tumors’ WHO Grade, 
histologic classification, location or other genetic alterations. Although the existence of tumor 
recurrences may be reflected in worst outcomes, no statistically significant differences were 
observed between the survival curves from tumors with and without CDKN2A gene deletion, 
suggesting that the CDKN2A gene deletion may not independently affect patients’ survival. 
Moreover, and in contrast with Horbinski, et al (2012)9 who identified homozygous deletions of 
CDKN2A gene in low and high-grade pediatric gliomas, in our series of tumors, homozygous 
deletions of the CDKN2A gene were only observed in 3 cases, all high-grade gliomas. 
Nevertheless, Steilen-Gimbel, et al (1999)45 hypothesized that the CDKN2A gene may already 
show a gene-dosage effect with a reduced proliferation-repressing function when it was 
heterozygously deleted.  
5- Histone genes mutations 
In human gliomas, all reported H3.3 mutations (K27M and G34R/V) have been identified 
in the H3F3A gene 12,36. In fact, the two genes (H3F3A and H3F3B) that encode the H3.3 histone 
were analyzed in this glioma cohort and genetic alterations were only found in the H3F3A gene. 
Following on Schwartzentruber, et al (2012)10 and Sturm, et al (2012)11, the results show that 
mutations in the H3F3A gene were related with tumor location and patients’ age: the K27M 
mutations occurred in brainstem gliomas and in younger patients (median and mean=7.5 years, 
range 5-10 years) and the G34R/V mutations in tumors located in the cerebral cortex and in 
older patients (median and mean=13 years; range 12-14 years). However, in the context of 
survival curves, a difference between these two groups in our series was not clearly identified, 
which may be ascribed to lack of information about some patients outcomes and to the small 
number of cases showing H3F3A mutations (n=7). Nevertheless, our results could demonstrate 
that the H3F3A-K27M mutation was associated with a shorter overall survival when compared 
to wild-type H3F3A cases.  
In contrast with the results presented by Kraushaar, et al (2013)37 and Wu, et al (2012)13, 
in our cohort of gliomas alterations in the H3.1 histone were not identified. However, in the 
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current work, only the HIST1H3I gene was analyzed and the genetic alterations in the H3.1 
histone have been reported to occur in the HIST1H3B gene 13. However, these alterations in the 
HIST1H3B gene have been only described in diffuse intrinsic pontine gliomas and in non-
brainstem pediatric glioblastomas, in low frequencies, 18% and 3%, respectively 13. In the 
analyzed population, these subtypes of gliomas were rare: 1 diffuse intrinsic pontine glioma and 
2 non-brainstem glioblastomas. 
The majority of studies about histone genes alterations in gliomas were performed using 
high-grade astrocytomas, mainly glioblastomas 1,11,13. The described incidence for the H3F3A-
K27M and H3F3A-G34R/V mutations in pediatric high-grade astrocytomas is 60-80% 1. However, 
in our glioma cohort, only 40% of the pediatric high-grade astrocytomas were H3F3A-K27M or 
H3F3A-G34R/V positive. Moreover, Schwartzentruber, et al (2012)10 and Gielen, et al (2013)38, 
showed that in pediatric population the H3F3A mutations occurred exclusively in high-grade 
astrocytomas. In contrast with these findings, we identified a H3F3A-K27M mutation in one 
anaplastic oligoastrocytoma (HGG1 – Figure IV.1 and Appendix 2) and a H3F3A-G34R mutation 
in one oligodendroglioma (HGG17 – Figure IV.1 and Appendix 2). Although further studies using 
larger cohorts of non-astrocytic high-grade gliomas are needed, the results suggest that these 
two subgroups of pediatric glioblastomas (K27M and G34R/V) can be extended to other 
histologic subtypes of pediatric high-grade gliomas. The same may be also true for the other 
four biologic subgroups described for pediatric glioblastomas (RTK-I, Mesenchymal, IDH and 
PXA-like). However, to stratify the studied PHGGs in these subgroups, it would be necessary to 
study genetic alterations in other genes, such as PDGFRA, EGFR, TP53, NF1, IDH1 and IDH2. 
6 – Recurrences  
Mistry, et al (2015)30 demonstrated a clinically distinct subtype of pediatric secondary 
high-grade gliomas that arises from primary low-grade gliomas, defined by BRAFV600E 
mutations and CDKN2A gene deletions. They show that these two genetic alterations are 
commonly identified in low- and secondary high-grade gliomas and occur concomitantly in 75% 
of the transformed low-grade gliomas. We could not confirm these observations. In our series, 
most of the secondary gliomas that arose from low-grade gliomas were also low-grade tumors. 
Moreover, in the study population, the BRAFV600E mutation and the CDKN2A gene deletion 
were only seen simultaneously in one case that did not recur. These results were not totally 
unexpected because Broniscer (2015)46 has pointed out some fragilities in the results presented 
by Mistry, et al (2015)30 in connection to a sampling error due to the inclusion of patients whose 
tumors were not histologically confirmed to be either low or high-grade gliomas as long as there 
was clinical and radiologic evidence to support that diagnosis. This had led to the identification 
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of some tumors as low-grade gliomas that experienced malignant transformation within 1 year 
or less after diagnosis, having been shown previously that the minimal latency for malignant 
transformation was 1.6 years 47. This argument may partly be extended to the present case, 
since there may be some weaknesses in not having analyzed all BRAFV600E positive gliomas for 
the CDKN2A gene deletion (and vice-versa) or, due to lack of quality or quantity of material, not 
having analyzed all primary and secondary tumors for all genetic alterations. 
Interestingly, in the three pairs of primary and secondary gliomas positive for the 
BRAFV600E mutation, this genetic alteration remained present in the secondary tumor, but in 
the only pair of primary and secondary gliomas positive for CDKN2A gene deletion, the 
secondary tumor did not show a deletion of the CDKN2A gene. Thus, further studies are 
important to understand how the therapeutic regimens, directed at the primary tumor, affect 
the genetic characteristics of secondary tumors.   
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VI - Conclusion: 
 The objective of the study was to determine the genetic profile of pediatric gliomas. 
Results suggest that the BRAF/KIAA1549 rearrangement can be used as a diagnostic marker in 
association with the tumor histologic classification for low-grade gliomas, and BRAFV600E 
mutation (associated with a longer overall survival) and CDKN2A gene deletion (associated with 
tumor’s recurrences) as prognostic makers. Identification of MYB, MYBL1 and FGFR1 
rearrangements by FISH did not seem to be useful as diagnostic or prognostic markers. 
Mutations in the H3F3A gene at codons 27 and 34 of exon 1 were shown to play an important 
role in the stratification, not only of pediatric glioblastomas but also of the other histologic 
subtypes of PHGGs. The same was not seen for H3F3B and HIST1H3I genes. 
 A cell line from a high-grade glioma harboring the BRAFV600E mutation, was 
established, which, may be used in future studies to test new therapeutic approaches.  
 In sum, the genetic profile of pediatric gliomas in the Portuguese population was 
determined for the first time, and this study contributed to the characterization of pediatric 
gliomas, giving new insights for future studies. Since FISH and Sanger’s sequencing can be 
performed in most clinical laboratories, the study supports that these techniques can be added 
to the current battery of tests used in pediatric gliomas, for the identification of genetic 
alterations with diagnostic and prognostic value.  
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VII – Future Perspectives: 
 Future studies are needed to verify if the BRAFV600E mutation can be used as an 
independent favorable prognostic factor in pediatric gliomas. It is also important to understand 
the mechanisms that lead to MYB upregulation in pediatric pilocytic astrocytomas, diffuse 
astrocytomas and high-grade gliomas. Further studies that use a sequencing methodology are 
needed to understand if the FGFR1 duplication involving the tyrosine kinase domain can be used 
as a diagnostic marker for diffuse gliomas and to understand if the different FGFR1 described 
mutations (N554K, V559M, N546K and K656E) may be used as diagnostic and/or prognostic 
markers.  
 More studies with larger cohorts of recurrent primary and secondary pediatric gliomas 
are needed to better understand tumor transformation and specific genetic alterations over 
time, such as CDKN2A gene deletion and BRAFV600E mutation. It is also very relevant for future 
studies to investigate how a specific therapeutic regimen affects the potential secondary 
tumors.  
 In future clinical trials, a genetic stratification of the patients should be done to avoid 
bias of the results.  The established cell line may be used for the development of target therapies 
and to understand their effects in the context of the accumulated genetic alterations that 
characterize a tumor. 
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Appendices: 
Appendix 1 – Solutions prepared for the experimental work 
PBS 10x: 
 80g of NaCl 
 2g of KCl 
 14.4g of  Na2HPO4 
 2.4g of KH2PO4  
 800ml of Distilled water 
 Adjust the pH to 7.3-7.4 
 Adjust final volume to 1l with distilled water  
Autoclave the solution and store at room temperature. 
 
SSC 20x:  
 175.3g of NaCl 
 88.2g of C6H5Na3O7.H2O 
 800ml of Distilled water 
 Adjust the pH to 5.2 or 7 
 Adjust final volume to 1l, with distilled water  
Autoclave the solution and store at room temperature. 
 
TN 10x:  
 157.6g of Tris-HCl 1M 
 87.6g NaCl 
 800ml Distilled water 
 Adjust the pH to 7.5 
 Adjust final volume to 1l with distilled water  
Autoclave the solution and store at room temperature 
 
WB2: 
 100ml TN10x pH=7.5 
 900ml Distilled water 
 Adjust the pH to 7.5  
 Add 500µl of Tween 20  
Store at room temperature 
 
2x SSC/Tween 20: 
 100ml of SSC 20x pH=7 
 900ml of Distilled water 
 Adjust the pH to 7.5  
 Add 500µl of Tween 20  
Store at room temperature 
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HCl 0.01N: 
 5ml of HCl 
 400ml of Distilled water 
 Adjust the pH to 2  
 Adjust the final volume to 500ml with Distilled water  
Autoclave the solution and store at room temperature 
 
Formamide 50%: 
 500ml of Formamide 
 100ml of SSC 20x pH=5.2 
 400ml of Distilled water 
 Adjust the pH to 7  
Store at 4˚C 
 
Pepsine P7000 (20mg/ml): 
In a tube of 15ml: 
 10ml Distilled water 
 200mg of pepsine 
Dissolve and aliquot: 500µl per tube  
 
Proteinase K (20mg/ml): 
To a final volume of 10ml: 
 200mg of Proteinase K 
 10ml of Distilled water 
 Filter the solution with a 0.22µm pore filter 
Aliquot and store at -20˚C 
 
Protease: 
 100mg of protease  
 10ml of Carlsberg solution 
 Dissolve and aliquot: 1000µl per tube 
 
MgCl2: 
 38.094g of MgCl2 
 400ml of Distilled water 
Exothermic reaction 
 Let the solution cool down  
 Filter the solution with a filter paper and with a 0.22µm pore filter 
Store at 4˚C 
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TNB: 
In a 15nml tube: 
 10ml of WB2 
 0.5g of Blocking Reagent 
 Dissolve using a rotator (for 30min) 
 Centrifuge: 20min. 14000rpm 
 Transfer the supernatant to 2ml and 1.5ml tubes 
Store at -20˚C 
 
Lysis Buffer (10mM TrisHCl. 400mM NaCl. 2mM EDTA): 
 5ml of Tris-HCl 2M pH=8 
 80ml of NaCl 5M 
 4ml of EDTA 0.5M pH=8 
 Adjust final volume to 1l with distilled water 
 Filter with a 0.22µm pore filter 
Store at room temperature 
 
3M NaAc pH=5.2: 
Para 50ml: 
 20.4g of NaAc.3H2O (nº lab 3) 
 35ml of H2O 
 Adjust the pH to 5.2 
 Adjust final volume to 50ml  
Store at room temperature 
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Appendix 2 – Detailed representation of the results obtained 
Supplementary Table 1 – Clinical features and genetic abnormalities of all 109 gliomas studied.   
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